Taysha Gene Therapies’ Post

📈 Vivistim clinical outcomes continue to trend alongside or better than the published data. Amanda Saylor, OTR/L, CNS, CBIS, presented a case study of a stroke survivor who improved his Fugl-Meyer upper extremity motor score from 20 to 33: ⚪ FMA-UE 4-5 months post-stroke = 18 ⚪ FMA-UE 7 months post-stroke = 20 Patient began Paired VNS Therapy 7 months post-stroke ⚪ FMA-UE after 6 weeks of Paired VNS Therapy = 33 ⚪ FMA-UE 1 year after beginning Paired VNS Therapy = 54 ⚪ Functional goals achieved: tying shoelaces with both hands & cutting food 👉 Paired VNS Therapy was not facilitated consistently for 12 months 👉 FMA-UE maximum score = 66 Visit https://bit.ly/3qmTqt9 to review our clinical bibliography, learn more about offering hope to stroke survivors with Vivistim Paired VNS Therapy and review safety information.

📈 Vivistim clinical outcomes continue to trend alongside or better than the published data. Amanda Saylor, OTR/L, CNS, CBIS, presented a case study of a stroke survivor who improved his Fugl-Meyer upper extremity motor score from 20 to 33: ⚪ FMA-UE 4-5 months post-stroke = 18 ⚪ FMA-UE 7 months post-stroke = 20 Patient began Paired VNS Therapy 7 months post-stroke ⚪ FMA-UE after 6 weeks of Paired VNS Therapy = 33 ⚪ FMA-UE 1 year after beginning Paired VNS Therapy = 54 ⚪ Functional goals achieved: tying shoelaces with both hands & cutting food 👉 Paired VNS Therapy was not facilitated consistently for 12 months 👉 FMA-UE maximum score = 66 Visit https://bit.ly/3qmTqt9 to review our clinical bibliography, learn more about offering hope to stroke survivors with Vivistim Paired VNS Therapy and review safety information.

TOMORROW: Key Strategies in Pediatric Clinical Trials – March 7. This webinar offers a concise overview of critical aspects in pediatric trials, from innovative specimen collection and assay development to the nuances of patient engagement. Ideal for anyone involved in pediatric research, this event is your opportunity to gain insights from experts in the field. Secure your spot now. https://hubs.ly/Q02nmnhH0 Eva Raschke #clinicaltrials #clinicalresearch #pediatricdrugdevelopment

TOMORROW: Key Strategies in Pediatric Clinical Trials – March 7. This webinar offers a concise overview of critical aspects in pediatric trials, from innovative specimen collection and assay development to the nuances of patient engagement. Ideal for anyone involved in pediatric research, this event is your opportunity to gain insights from experts in the field. Secure your spot now. https://hubs.ly/Q02nmsmW0 Eva Raschke #clinicaltrials #clinicalresearch #pediatricdrugdevelopment

From @BU_CME: Overcoming Barriers to Effective Treatment and Enrollment in Clinical Trials for Black and Underserved Patients With Multiple Myeloma https://lnkd.in/d4Mz32bF

ICYMI - Check out the latest post from #TranslationalBytes and learn more about locally acting drugs and how they can be used for pediatric patients: https://bit.ly/3VInqMk

Identifying the effects of #neurorehabilitation treatment is challenging. In this review paper, Drs. Forsyth and Whyte characterize the mechanisms of action of pediatric rehabilitation ingredients for a better understanding of the potential differences neurorehabilitation can make. Read more: https://lnkd.in/ebw6Kuyw

Over the past decade, there's been a notable surge in anticoagulation therapies for pediatric patients, with up to 15% of hospitalized children benefiting from #heparin or heparinoids. Frequent monitoring of Anti Factor Xa activity (aFXa) is crucial for children on heparin therapy, sometimes up to 2-3 times per day, to maintain therapeutic levels. However, current tests often require large blood volumes, posing a risk of iatrogenic anemia in neonates. Read this interesting blog on the "Unique Challenges to Heparin Monitoring in Neonatal and Pediatric Populations" and how Baebies' #DigitalMicrofluidics (#DMF) technology is addressing this challenge using only ~50 µL whole blood input with ~14 minutes time to result. Such a test would enable pediatric heparin therapy management, providing clinicians with timely data. Link: https://lnkd.in/gV4qvQEz #AnytestAnywhereEveryone #Heparin

New phase 3 data on #linaclotide for functional #constipation in pediatric patients aged 6 to 17 years. Linaclotide-treated patients achieved a greater than 2-fold least squares mean change from baseline in SBMs/week (2.220) vs placebo (1.050) (P < 0.0001). MORE: https://lnkd.in/ep5NY9HS

Renal replacement therapy during pediatric #ECMO, an ELSO Registry study including > 14K runs 🫘 RRT common: 26% of children received #RRT during #ECLS 🫘 need for RRT before/during ECMO independent predictor for mortality to decannulation & to hospital discharge 🫘 initiating RRT 24-72h seems to provide a survival advantage vs initiating before 24h/after 72h ASAIO Journal #PedsICU 🖇️ https://bit.ly/49i1kWc